

# **Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice**

Aug 30, 2017

---

**Source URL:** <https://qa1.novartis.us/us-en/news/media-releases/multimedia-assets-now-available-novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-tisagenlecleucel-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice-0>

## **List of links present in page**

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/multimedia-assets-now-available-novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-tisagenlecleucel-ctl019-children-and-young-adults-b-cell-all-refractory-or-has-relapsed-least-twice-0>